Stepan Company, announced that it has entered into credit agreement providing for a five-year committed $350 million multi-currency revolving credit facility and a $100...
Biofluidica announced the results of a breast cancer study comparing invasive needle biopsies with their non-invasive, highly sensitive Next-Generation Liquid Biopsy platform, LiquidScan™ to...
Antios Therapeutics, Inc. (Antios), a clinical-stage biopharmaceutical company developing transformative treatments for hepatitis B virus (HBV), announced new data from the Phase 2a clinical...
